TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30665504

Group type: EXPERIMENTAL
Intervention: 1 L of normal saline solution during 1 hour
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline solution at 10 mL/hour for 1 hour (control group)
Number of subjects: 49
Study: 27858693

Group type: EXPERIMENTAL
Intervention: Kinesiotape
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham tape (control)
Number of subjects: 2
Study: 25274266

Group type: EXPERIMENTAL
Intervention: LDRnHBT (Low-dose radon hyperthermia balneo treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PlaceboHBT (radon-free thermal water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined hyperthermia balneo and exercise treatment
Number of subjects: 0
Study: 24930817

Group type: EXPERIMENTAL
Intervention: Reduced-calorie weight-loss diet and exercise program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study: 22870723

Group type: EXPERIMENTAL
Intervention: Modified skin flap of external canal
Number of subjects: 412

Group type: COMPARATOR
Intervention: Traditional skin flap of external canal
Number of subjects: 412
Study: 19324944

Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (1 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trigonelline (500 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (1 g mannitol)
Number of subjects: 15
Study: 16839826

Group type: EXPERIMENTAL
Intervention: PariLC+ nebuliser
Number of subjects: 10

Group type: COMPARATOR
Intervention: NL9M nebuliser
Number of subjects: 10
Study: 15157948

Group type: COMPARATOR
Intervention: FMS patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: CFS patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pulsatility analyses
Number of subjects: 40
Study: 11522582

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg daily subcutaneous injections
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 233
Study: 9928557

Group type: EXPERIMENTAL
Intervention: Liposuction and axilloscopy
Number of subjects: 50
Study: 7920875

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD, 514 and 470 Kcal/day in women and men respectively)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (baseline measurements)
Number of subjects: 52
Study: 3291074

Group type: EXPERIMENTAL
Intervention: High doses of diethylcarbamazine (DEC) - 30 mg/kg/d for one week preceded by a one week initial treatment with normal oral doses of DEC or DEC lotion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single dose of ivermectin (150 micrograms/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31789711

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (ARNI)
Number of subjects: 2165

Group type: EXPERIMENTAL
Intervention: Fully eligible patients
Number of subjects: 2165

Group type: EXPERIMENTAL
Intervention: Partially eligible patients
Number of subjects: 2165

Group type: EXPERIMENTAL
Intervention: Fully and partially eligible patients
Number of subjects: 2165
Study: 29420189

Group type: EXPERIMENTAL
Intervention: DOUBLE (double-dose clopidogrel)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: TRIPLE (adjunctive cilostazol)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: STANDARD (standard dual antiplatelet therapy)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: DOUBLE
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: TRIPLE
Number of subjects: 1078
Study: 28737440

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study: 26248059

Group type: EXPERIMENTAL
Intervention: Needle
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiocath
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 132
Study: 24088688

Group type: EXPERIMENTAL
Intervention: Integration of family planning services into HIV care and treatment clinics
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard-of-care with separately delivered family planning and HIV services
Number of subjects: 12
Study: 20505750

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-NMMA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study: 19081890

Group type: EXPERIMENTAL
Intervention: Vector system (Durr Dental)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Handheld instruments
Number of subjects: 41
Study: 16624583

Group type: EXPERIMENTAL
Intervention: Looking at pictures of abstract art with no explicit instruction to remember
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Explicit instruction to remember the stimuli
Number of subjects: 20
Study: 12356000

Group type: EXPERIMENTAL
Intervention: Indapamid SR 1.5 mg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 524
Study: 10583349

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 1366
Study: 8756842

Group type: EXPERIMENTAL
Intervention: Transanal mucosectomy with handsewn anastomosis (Group I, 13 cases)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Double-stapled technique (Group II, 15 cases)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-stapled anastomosis with preservation of the anal transition zone (Group III, 12 cases)
Number of subjects: 40
Study: 1918848

Group type: EXPERIMENTAL
Intervention: Intraportal nitroglycerin (1 microgram/kg/min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin (1 microgram/kg/min)
Number of subjects: 18
Study: 7036801

Group type: EXPERIMENTAL
Intervention: Ancrod (Arvin)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 27
Study: 29073785

Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 27091717

Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroid prophylaxis (group B, n = 72)
Number of subjects: 228

Group type: COMPARATOR
Intervention: No corticosteroid prophylaxis (group C, n = 73)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroid prophylaxis (group B)
Number of subjects: 228
Study: 25608587

Group type: EXPERIMENTAL
Intervention: Isoniazid treatment
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Negative or indeterminate IGRA results
Number of subjects: 263
Study: 23930203

Group type: EXPERIMENTAL
Intervention: Hybrid liposomes (HL-23)
Number of subjects: 0
Study: 21039933

Group type: EXPERIMENTAL
Intervention: Garlic extract supplementation at 250 mg/kg BW/day/calf
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no garlic extract)
Number of subjects: 12
Study: 18560524

Group type: EXPERIMENTAL
Intervention: Concentrated ambient fine and ultrafine particles (CAPs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Filtered air (Control)
Number of subjects: 24
Study: 16775418

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m(2))
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Docetaxel (15 mg/m(2)) with ketoconazole (400 mg 3 times daily)
Number of subjects: 7
Study: 12705363

Group type: EXPERIMENTAL
Intervention: Genotropin ZipTip needle-free device
Number of subjects: 133

Group type: COMPARATOR
Intervention: Genotropin Pen (fine-gauge needle)
Number of subjects: 133
Study: 11253342

Group type: EXPERIMENTAL
Intervention: External compression (intermittent by pneumatic pumps, continuous by anelastic or elastic bandages, and graduated compression stockings)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External compression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External compression with early mobilization and Low Molecular Weight Heparin (LMWH) therapy
Number of subjects: 0
Study: 9189045

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 900 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baclofen (up to 30 mg/day)
Number of subjects: 21
Study: 7694617

Group type: EXPERIMENTAL
Intervention: Modified Kleinert dynamic splint
Number of subjects: 37

Group type: COMPARATOR
Intervention: Original Kleinert dynamic splint
Number of subjects: 37
Study: 3697615

Group type: EXPERIMENTAL
Intervention: d(15)+Be neutrons
Number of subjects: 34

Group type: COMPARATOR
Intervention: 4 MV photons
Number of subjects: 34
Study: 30457433

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/eFlow CS 50 μg twice daily
Number of subjects: 620

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily (administered via HandiHaler™)
Number of subjects: 620
Study: 28544344

Group type: EXPERIMENTAL
Intervention: MPH XR-ODT (60 mg) administered in a fed state
Number of subjects: 48

Group type: COMPARATOR
Intervention: MPH XR-ODT (60 mg) administered in a fasted state
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MPH XR-ODT (60 mg)
Number of subjects: 48
Study: 26152608

Group type: EXPERIMENTAL
Intervention: Patient intervention (Phase 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Provider intervention (Phase 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Patient intervention only (Phase 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 120
Study: 25306591

Group type: EXPERIMENTAL
Intervention: Normal bone mass
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Osteopenia
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Osteoporosis
Number of subjects: 83
Study: 22353395

Group type: EXPERIMENTAL
Intervention: BAY 86-6150 (6.5, 20, 50 or 90 μg kg(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20826592

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (rIC) - 4 cycles of 5 minutes upper-limb ischemia during transfer to primary percutaneous coronary intervention (pPCI)
Number of subjects: 242

Group type: COMPARATOR
Intervention: pPCI alone
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (rIC)
Number of subjects: 242
Study: 18853615

Group type: EXPERIMENTAL
Intervention: Mirazid (10 mg/kg for 2 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paromomycin (500 mg qid for 2 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of Mirazid (10 mg/kg) and Paromomycin (500 mg) for two weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 15668467

Group type: EXPERIMENTAL
Intervention: R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 122

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 122
Study: 12827065

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulants (general)
Number of subjects: 0
Study: 10669150

Group type: EXPERIMENTAL
Intervention: Daily 2 mg micronised oestradiol (E2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily 2 mg micronised oestradiol combined with a progestagen for 14 days of each cycle (E2+P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily 2 mg micronised oestradiol (E2) and E2+P
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study: 8797400

Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium (2.5 mg albuterol + 0.5 mg ipratropium)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Albuterol alone (2.5 mg)
Number of subjects: 384
Study: 1468911

Group type: EXPERIMENTAL
Intervention: Tizanidine (6 mg/day, increased to 18 mg/day based on response)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 3979577

Group type: EXPERIMENTAL
Intervention: Low-dose danazol (100 mg/24 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31746880

Group type: EXPERIMENTAL
Intervention: High protein concentration with normal protein ratio (80 casein:20 whey)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein concentration with modified protein ratio (40 casein:60 whey)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water-permeate control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein treatments (both ratios)
Number of subjects: 0
Study: 29426272

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (E2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Exercise (access to running wheel)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ovariectomized rats without estrogen
Number of subjects: 3
Study: 27353847

Group type: EXPERIMENTAL
Intervention: Statins and a CoQ analogue (experimental group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Statins alone (control group)
Number of subjects: 45
Study: 24626068

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study: 21906546

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention delivered on CD-ROM
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention delivered in print
Number of subjects: 442

Group type: COMPARATOR
Intervention: Generic information condition
Number of subjects: 442
Study: 16214825

Group type: EXPERIMENTAL
Intervention: Azathioprine therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High-risk group defined by ITPA 94C > A or TPMT <10 nmol/(mL erythrocytes . h)
Number of subjects: 71
Study: 12109175

Group type: EXPERIMENTAL
Intervention: Healthy Body Image: Teaching Kids to Eat and Love Their Bodies Too! curriculum
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control group (not exposed to the curriculum)
Number of subjects: 415
Study: 9783399

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza split vaccine (IIV)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Live trivalent influenza allantoic vaccine (LIV)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combined use of IIV and LIV
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combined vaccination (IIV + LIV)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Inactivated trivalent influenza split vaccine (IIV) alone
Number of subjects: 600

Group type: COMPARATOR
Intervention: Live trivalent influenza allantoic vaccine (LIV) alone
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Vaccination schedule with IIV followed by revaccination with LIV 3-4 weeks later
Number of subjects: 600
Study: 8072991

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg and 1200 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diets
Number of subjects: 41

Group type: COMPARATOR
Intervention: Predian
Number of subjects: 41

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sugar-reducing drugs and insulin
Number of subjects: 41
Study: 3383879

Group type: EXPERIMENTAL
Intervention: Molsidomine (8 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11685297

Group type: EXPERIMENTAL
Intervention: TLC C-53 (liposomal prostaglandin E1)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 31203726

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the renal main arteries
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined radiofrequency ablation of the main and branch arteries
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ultrasound-based ablation of the main renal artery
Number of subjects: 120
Study: 29603781

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27403645

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo add-on
Number of subjects: 100
Study: 24606097

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (40,000 IU weekly)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22984018

Group type: EXPERIMENTAL
Intervention: Subtotal or gross total resections
Number of subjects: 526

Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 526
Study: 19825207

Group type: EXPERIMENTAL
Intervention: 20 g dark chocolate with 500 mg polyphenols
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 g dark chocolate with 1000 mg polyphenols
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both doses of dark chocolate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 14
Study: 17885595

Group type: EXPERIMENTAL
Intervention: Subliminal words presented with long interstimulus intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single presentation of a masked word
Number of subjects: 0
Study: 16083519

Group type: EXPERIMENTAL
Intervention: Zolmitriptan ODT
Number of subjects: 186
Study: 11879129

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 419
Study: 9689420

Group type: EXPERIMENTAL
Intervention: Sustained release tablet (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference preparation (20 mg)
Number of subjects: 10
Study: 7857348

Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg ampoule twice a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 50
Study: 2776821

Group type: EXPERIMENTAL
Intervention: verapamil-SR 360 mg once daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: verapamil-IR 120 mg t.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: verapamil-SR 240 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: verapamil-SR
Number of subjects: 10

Group type: COMPARATOR
Intervention: verapamil-IR
Number of subjects: 10
Study: 1110438

Group type: EXPERIMENTAL
Intervention: Extra contact with infants during the neonatal period
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (less contact with infants)
Number of subjects: 10
Study: 31032913

Group type: EXPERIMENTAL
Intervention: Chronic Migraine (CM)
Number of subjects: 516
Study: 29143926

Group type: EXPERIMENTAL
Intervention: Moisturizer plus body wash (twice daily moisturizer and once daily body wash)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Body wash alone (once daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Moisturizer plus body wash
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 64
Study: 25664642

Group type: EXPERIMENTAL
Intervention: Personalized feedback only intervention (PFB)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Education only (EDU)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 333
Study: 23349102

Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich bilberry pomace extract (BE)
Number of subjects: 0
Study: 22048089

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with acromioplasty
Number of subjects: 68

Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without acromioplasty
Number of subjects: 68
Study: 19371267

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg day(-1))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pravastatin (10 mg day(-1))
Number of subjects: 44
Study: 17029278

Group type: EXPERIMENTAL
Intervention: BTX type A (BTX‐A) plus a specific program of physical therapy (BTX‐PT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BTX type A (BTX‐A) alone (BTX‐0)
Number of subjects: 40
Study: 15028348

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 428
Study: 11394701

Group type: EXPERIMENTAL
Intervention: Low concentrate citrate lock
Number of subjects: 19

Group type: COMPARATOR
Intervention: Heparin lock
Number of subjects: 19
Study: 9119756

Group type: EXPERIMENTAL
Intervention: Contralateral broad-band noise at 60 dB SPL RMS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Contralateral broad-band noise
Number of subjects: 4
Study: 8098788

Group type: EXPERIMENTAL
Intervention: Gln TPN (parenteral nutrition enriched with glycyl‐L‐glutamine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: STPN (standard parenteral nutrition)
Number of subjects: 20
Study: 3548350

Group type: EXPERIMENTAL
Intervention: Suramin (0.5, 1.0, or 1.5 g weekly for up to six months)
Number of subjects: 41
Study: 29480316

Group type: EXPERIMENTAL
Intervention: 0.2 g oat β-glucan (OBG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.4 g oat β-glucan (OBG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.6 g oat β-glucan (OBG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Instant oatmeal plus 247 g 2% milk (IO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cream of rice (CR) plus milk
Number of subjects: 40
Study: 27595528

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin/day for 2 days preoperatively
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 40 mg of atorvastatin/day for 5‐9 days preoperatively
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin/day for 5‐9 days preoperatively
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 94
Study: 25029347

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sham OMT
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cervical pain, headache, and quality of life (QOL)
Number of subjects: 32